Amyotrophic Lateral Sclerosis
Conditions
Brief summary
The effect of autologous bone marrow mononuclear cells on duration of survival in Amyotrophic Lateral Sclerosis patients.
Detailed description
Survival duration in Amyotrophic Lateral Sclerosis patients who received cellular transplantation was compared to patients who did not receive cellular transplantation. Kaplan-Meier survival analysis was used for this comparison.
Interventions
BIOLOGICALStem cell
Autologous bone marrow derived mononuclear cells were administered via intrathecal and intramuscular routes.
Sponsors
Neurogen Brain and Spine Institute
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
26 Years to 76 Years
Healthy volunteers
No
Inclusion criteria
* Patients with the diagnoses of definite amyotrophic lateral sclerosis. * Clear information about date of onset of symptoms, documented contact information and follow up information
Exclusion criteria
* Patients with diagnoses of Progressive Lateral sclerosis, Progressive bulbar plasy, Progressive spinal muscular atrophy, Progressive muscular atrophy, monomelicamyotrophy or madras motor neuron disease. * patients with co-morbidities like presence of acute infections such as Human Immunodeficiency Virus/Hepatitis B Virus/Hepatitis C Virus, malignancies, bleeding tendencies, renal failure, severe liver dysfunction and other acute medical conditions such as respiratory infection and pyrexia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of survival | 56 months |
Countries
India
Outcome results
None listed